Aftertrade Broking Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Draft Letter of Offer to the Public Shareholders of Aspira Pathlab & Diagnostics Ltd ("Target Company").
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250 and 1.2 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aftertrade Broking Pvt Ltd, acting as Manager to the Offer, has submitted a Draft Letter of Offer to BSE on behalf of five acquirers from the Bhanushali family along with one Person Acting in Concert (PAC). The open offer is being made under SEBI (SAST) Regulations 2011 to acquire up to 26,76,180 equity shares (26% of total voting share capital) of Aspira Pathlab & Diagnostics at ₹55 per share, totaling approximately ₹14.72 crores in maximum consideration. The offer is triggered by a substantial acquisition accompanied with change in control. If fully accepted, the acquirers and PAC will collectively hold 49.82% of the company. The offer opens on November 24, 2025 and closes on December 5, 2025.
Public shareholders now have a defined window to tender shares at ₹55 each and exit if they wish. The offer signals a change in control of the company, and the stock may see price movement around the offer dates based on the gap between market price and the offer price.